Skip to main
CRBP

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals is an innovative biopharmaceutical company with a diverse pipeline of therapies targeting various oncological and metabolic conditions. The company's CRB-701, CRB-601, and CRB-913 show promising results in clinical trials, with strong efficacy and safety profiles. With a clear regulatory path and a strategic enrollment strategy in place, Corbus is well-positioned for success, and the potential launch of its therapies could drive significant financial growth in the future.

Bears say

Corbus Pharmaceuticals is focused on developing innovative therapies in oncology and obesity, with a focus on targeting well-understood biological pathways. However, the company's financial and clinical data suggest a lack of success in bringing these therapies to market, leading to a negative outlook on the stock's potential for growth and profitability. The company's recent data updates show a potential for a high unmet need in the target population, but questions remain regarding the feasibility and effectiveness of their treatment options. Based on this, the analyst maintains an OUTPERFORM rating and adjusts the price target to $30, anticipating a more conservative market for their Nectin-4 targeted therapy, CRB-701.

CRBP has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 7 analysts, CRBP has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.